← Leaderboards
Michael T Chin
Brigham And Women'S Hospital
$13,258,737
Attributed
$13,258,737
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,258,737 · 11
By mechanism
R01$5,679,888 · 4
T32$3,367,301 · 2
P50$1,639,168 · 1
R61$1,224,640 · 1
R33$623,000 · 1
R21$478,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Yvette Y Yien$5,794,587
- Michael S Wolfe$15,472,448
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureAffectIn VitroSerumCellsIn VivoMouse ModelAnimalsHeartTranscription FactorMuscle CellsMyocardiumCardiac MyocytesBaseIncidenceMediatingHeart HypertrophyHypertrophyStimulusResponsePathogenesisLinkDefectGene Expression
Grant awards (37)
Medical Scientist Training Program at Tufts University$466,360
T32 · FY2025 · GM · contact PI
Medical Scientist Training Program at Tufts University$599,359
T32 · FY2024 · GM · contact PI
Functional assay development for tafazzin enzyme replacement candidate selection$623,000
R33 · FY2023 · HL · contact PI
Medical Scientist Training Program at Tufts University$580,535
T32 · FY2023 · GM · contact PI
Functional assay development for tafazzin enzyme replacement candidate selection$601,640
R61 · FY2022 · HL · contact PI
Medical Scientist Training Program at Tufts University$570,362
T32 · FY2022 · GM · contact PI
Functional assay development for tafazzin enzyme replacement candidate selection$623,000
R61 · FY2021 · HL · contact PI
Medical Scientist Training Program at Tufts University$537,629
T32 · FY2021 · GM · contact PI
Administrative Supplements for Curriculum or Training Activities to Enhance Wellness and Resiliency in the Training Environment$81,000
T32 · FY2021 · GM · contact PI
Medical Scientist Training Program at Tufts University$532,056
T32 · FY2020 · GM · contact PI
Intracellular mitochondrial enzyme replacement therapy for heart and skeletalmyopathy in Barth Syndrome$336,875
R01 · FY2019 · GM · contact PI
Intracellular mitochondrial enzyme replacement therapy for heart and skeletalmyopathy in Barth Syndrome$336,875
R01 · FY2018 · GM · contact PI
Intracellular mitochondrial enzyme replacement therapy for heart and skeletalmyopathy in Barth Syndrome$336,875
R01 · FY2017 · GM · contact PI
Intracellular mitochondrial enzyme replacement therapy for heart and skeletal myopathy in Barth Syndrome$337,036
R01 · FY2016 · GM · contact PI
In utero and early life diesel exposure, epigenetic modification and heart failur$217,500
R21 · FY2015 · ES · contact PI
In utero and early life diesel exposure, epigenetic modification and heart failur$261,000
R21 · FY2014 · ES · contact PI
Project 4: Myocardial Inury and Apoptosis with DE Exposure$341,738
P50 · FY2012 · ES · contact PI
Project 4: Myocardial Inury and Apoptosis with DE Exposure$324,252
P50 · FY2011 · ES · contact PI
Project 4: Myocardial Inury and Apoptosis with DE Exposure$330,829
P50 · FY2010 · ES · contact PI
Role of CHF1/Hey2 in Hypertrophy and Heart Failure$402,965
R01 · FY2009 · HL · contact PI
Project 4: Myocardial Inury and Apoptosis with DE Exposure$325,548
P50 · FY2009 · ES · contact PI
Role of CHF1/Hey2 in Hypertrophy and Heart Failure$402,965
R01 · FY2008 · HL · contact PI
Role of CHF1 in Occlusive Vascular Disease$393,495
R01 · FY2008 · HL · contact PI
Project 4: Myocardial Inury and Apoptosis with DE Exposure$316,801
P50 · FY2008 · ES · contact PI
Role of CHF1/Hey2 in Hypertrophy and Heart Failure$402,965
R01 · FY2007 · HL · contact PI
Role of CHF1 in Occlusive Vascular Disease$393,495
R01 · FY2007 · HL · contact PI
Role of CHF1 in Occlusive Vascular Disease$379,057
R01 · FY2006 · HL · contact PI
Role of CHF1/Hey2 in Hypertrophy and Heart Failure$240,653
R01 · FY2006 · HL · contact PI
Role of CHF1/Hey2 in Hypertrophy and Heart Failure$131,215
R01 · FY2006 · HL · contact PI
Role of CHF1 in Occlusive Vascular Disease$1
R01 · FY2006 · HL · contact PI
Role of CHF1 in Occlusive Vascular Disease$368,416
R01 · FY2005 · HL
Role of CHF1 in Cardiovascular Development$304,250
R01 · FY2004 · HL
Role of CHF1 in Cardiovascular Development$304,250
R01 · FY2003 · HL
Role of CHF1 in Cardiovascular Development$304,250
R01 · FY2002 · HL
Role of CHF1 in Cardiovascular Development$304,250
R01 · FY2001 · HL
HMG-I Y AND ARTERIOSCLEROSIS$123,120
K08 · FY2001 · HL
HMG-I Y AND ARTERIOSCLEROSIS$123,120
K08 · FY2000 · HL